Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) has been given a consensus recommendation of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $47.60.
Several analysts recently commented on the company. Cowen dropped their price target on Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a research report on Monday. Cowen dropped their target price on shares of Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a report on Monday.
Get Emergent BioSolutions alerts:Institutional Investors Weigh In On Emergent BioSolutions
Several hedge funds and other institutional investors have recently bought and sold shares of EBS. State of Alaska Department of Revenue lifted its stake in shares of Emergent BioSolutions by 1.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 33,825 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 430 shares during the last quarter. Covestor Ltd lifted its position in Emergent BioSolutions by 43.8% in the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 491 shares during the last quarter. Cutler Group LP boosted its stake in Emergent BioSolutions by 250.0% during the first quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 500 shares during the period. Kendall Capital Management raised its stake in shares of Emergent BioSolutions by 4.7% in the 1st quarter. Kendall Capital Management now owns 11,585 shares of the biopharmaceutical company's stock valued at $476,000 after acquiring an additional 525 shares during the period. Finally, Centaurus Financial Inc. boosted its position in shares of Emergent BioSolutions by 14.4% during the 2nd quarter. Centaurus Financial Inc. now owns 4,342 shares of the biopharmaceutical company's stock worth $135,000 after purchasing an additional 546 shares during the period. 81.54% of the stock is currently owned by institutional investors and hedge funds.
Emergent BioSolutions Stock Down 0.7 %
Shares of NYSE EBS opened at $22.72 on Monday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of 13.44 and a beta of 1.07. The company's 50-day simple moving average is $28.97 and its 200-day simple moving average is $33.57. The company has a quick ratio of 2.38, a current ratio of 3.92 and a debt-to-equity ratio of 0.52. Emergent BioSolutions has a 52-week low of $21.86 and a 52-week high of $58.33.Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($1.24). Emergent BioSolutions had a return on equity of 12.22% and a net margin of 6.02%. The firm had revenue of $242.70 million during the quarter, compared to analyst estimates of $268.77 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company's quarterly revenue was down 38.9% on a year-over-year basis. Equities analysts predict that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.
Emergent BioSolutions Company Profile
(Get Rating)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
See Also
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.